AbbVie says Rinvoq shines again as maintenance therapy for ulcerative colitis — but safety concerns still loom over JAK class
Even as Rinvoq gets swept up in the FDA’s look into the safety of JAK inhibitors as a class, AbbVie is continuing to roll …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
